These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29018147)

  • 1. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy.
    Wang J; Hu Y; Huang H
    J Leukoc Biol; 2017 Dec; 102(6):1347-1356. PubMed ID: 29018147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.
    Hu Y; Wu Z; Luo Y; Shi J; Yu J; Pu C; Liang Z; Wei G; Cui Q; Sun J; Jiang J; Xie J; Tan Y; Ni W; Tu J; Wang J; Jin A; Zhang H; Cai Z; Xiao L; Huang H
    Clin Cancer Res; 2017 Jul; 23(13):3297-3306. PubMed ID: 28039267
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy for ALL.
    Maude SL; Shpall EJ; Grupp SA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
    Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia.
    Biondi A; Magnani CF; Tettamanti S; Gaipa G; Biagi E
    J Autoimmun; 2017 Dec; 85():141-152. PubMed ID: 28843422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling.
    Nair S; Wang JB; Tsao ST; Liu Y; Zhu W; Slayton WB; Moreb JS; Dong L; Chang LJ
    Curr Gene Ther; 2019; 19(1):40-53. PubMed ID: 30444200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances of treatment study on acute lymphoblastic leukemia with chimeric antigen receptor modified T cells].
    Weng WW; Tang YM
    Zhonghua Er Ke Za Zhi; 2019 Aug; 57(8):643-646. PubMed ID: 31352754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 16. CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
.
    Callahan C; Baniewicz D; Ely B
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):22-28. PubMed ID: 28315553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
    Grupp SA; Kalos M; Barrett D; Aplenc R; Porter DL; Rheingold SR; Teachey DT; Chew A; Hauck B; Wright JF; Milone MC; Levine BL; June CH
    N Engl J Med; 2013 Apr; 368(16):1509-1518. PubMed ID: 23527958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in chimeric antigen receptor T cell therapy.
    Maude SL
    Curr Opin Pediatr; 2017 Feb; 29(1):27-33. PubMed ID: 27841776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
    Ruella M; Barrett DM; Kenderian SS; Shestova O; Hofmann TJ; Perazzelli J; Klichinsky M; Aikawa V; Nazimuddin F; Kozlowski M; Scholler J; Lacey SF; Melenhorst JJ; Morrissette JJ; Christian DA; Hunter CA; Kalos M; Porter DL; June CH; Grupp SA; Gill S
    J Clin Invest; 2016 Oct; 126(10):3814-3826. PubMed ID: 27571406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.